Product Description
A potent and selective second generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. Renazorb binds to phosphates and forms an insoluable lanthanum phosphate complex which is expected to reduce serum phosphate levels in ESRD patients. (Sourced from: https://www.sppirx.com/336-spectrum-products-development-spi014.html)
Mechanisms of Action: Phosphate Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SPI-014 | P1 |
Completed |
Kidney Diseases |
2012-09-01 |